Lab21 launches cytomegalovirus test for blood transfusions
This article was originally published in Clinica
Lab21 has launched a test for cytomegalovirus (CMV) in human serum and plasma. The enzyme immunoassay, now available worldwide excluding the US, is intended to screen donated blood for the virus, minimising the risk of transmission. It is "significantly more sensitive than other CMV assays that are currently commercially available", Cambridge, UK-based Lab21 claims. CMV, from the herpes family of viruses, generally causes very few symptoms or none at all. However, it can lead to significant health problems in immunocompromised people, such as HIV patients or transplant recipients, and foetuses. The company CE marked the diagnostic on November 13, and plans to seek US FDA 510(k) approval "in due course", a spokesperson told Clinica.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.